Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.47 |
| ▸ | ARG1 | P05089 | 1/20 | 0.41 |
| ▸ | ARG2 | P78540 | 1/20 | 0.41 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 5/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10956783 | 0.91 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3HRH3ARG1 | |
| SCHEMBL440476 | 0.91 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3HRH3ARG1 | |
| SCHEMBL414249 | 0.91 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3HRH3ARG1 | |
| Hydrochloric Acid SCHEMBL7375378 | 0.89 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3HRH3ARG1 | |
| SCHEMBL8083651 | 0.86 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3HRH3ARG1 | |
| SCHEMBL7455945 | 0.86 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3HRH3ARG1 | |
| SCHEMBL11234764 | 0.85 | HRH3 (0.56) | SLC6A2SLC6A4SLC6A3HRH3ARG1 | |
| SCHEMBL1819135 | 0.85 | HRH3 (0.56) | SLC6A2SLC6A4SLC6A3HRH3ARG1 | |
| SCHEMBL4849081 | 0.84 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3HRH3ARG1 | |
| SCHEMBL1816048 | 0.84 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3HRH3ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-03-12 | — | — | US | disclosed |
| EP-4299134-A2 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | Bach Biosciences, LLC (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3154594-B1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-11302421-B2 | Data storage using peptides | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2022-04-12 | — | — | US | disclosed |
| US-11266669-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2022-03-08 | — | — | US | disclosed |
| US-20210308090-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES LLC (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210275491-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2021-09-09 | — | — | US | disclosed |
| US-11033525-B2 | Fap-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210090688-A1 | Data storage using peptides | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2021-03-25 | — | — | US | disclosed |
| WO-2009149148-A2 | LONG-ACTING GLP-1 DERIVATIVES, AND METHODS OF TREATING CARDIAC DYSFUNCTION | TRUSTEES OF TUFTS COLLEGE (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009006473-A2 | PRO-SOFT POLYPEPTIDE PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008128064-A2 | TRUNCATED ANALOGS OF PEPTIDE AND POLYPEPTIDE THERAPEUTICS | TRUSTEES OF TUFTS COLLEGE (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008119005-A1 | 3,4-DEHYDRO-PROLINE-CONTAINING INHIBITORS OF DIPEPTIDYLPEPTIDASE IV | TRUSTEES OF TUFTS COLLEGE (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118848-A1 | N-SUBSTITUTED PEPTIDOMIMETIC INHIBITORS OF DIPEPTIDYLPEPTIDASE IV | TRUSTEES OF TUFTS COLLEGE (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116053-A2 | FAP-ACTIVATED CHEMOTHERAPEUTIC COMPOUNDS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-09-25 | — | — | WO | disclosed |
| EP-1948243-A2 | POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF | Aeris Therapeutics, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2008022015-A2 | RETRO-INVERSO INCRETIN ANALOGUES, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007055950-A2 | POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF | AERIS THERAPEUTICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070110813-A1 | Polycation-polyanion complexes, compositions and methods of use thereof | AERIS THERAPEUTICS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11266669-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | SLC6A2 4581/4885SLC6A4 4650/4885SLC6A3 4716/4885 |
| US-11033525-B2 | Fap-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | SLC6A2 4281/4885SLC6A4 4306/4885SLC6A3 4546/4885 |
| US-20210275491-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | SLC6A2 4281/4885SLC6A4 4306/4885SLC6A3 4546/4885 |
| US-20210308090-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | SLC6A2 4281/4885SLC6A4 4306/4885SLC6A3 4546/4885 |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | SLC6A2 4281/4885SLC6A4 4306/4885SLC6A3 4546/4885 |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | SLC6A2 4600/4885SLC6A4 4665/4885SLC6A3 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.